Oxford Biomedica

Oxford Biomedica is a UK-based company with a leading position in cancer immunotherapy and gene-based products. It is focusing its efforts on two clinical programmes, ProSavin and TroVax, and has an ocular collaboration with Sanofi-Aventis.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Actinogen Medical – equity proposition

Uncovering Trusts – Patria Private Equity Trust (PPET) – A gateway to top European private equity managers

Greggs – executive interview

About Edison

About Edison

Careers

Oxford Biomedica (LSE: OXB)

Latest Insights

Oxford Biomedica — COVID vaccine and Kymriah news encouraging

Oxford Biomedica: Edison Open House Healthcare 2022

Oxford Biomedica — Driving innovation in a thriving CGT industry

Oxford Biomedica – executive interview

Sector

Research

Oxford Biomedica — OxBox investment to aid future growth

Oxford BioMedica — Novartis extends commercial supply agreement

Oxford BioMedica — Juno deal expands CAR-T revenue streams

Oxford Biomedica — Investing for future growth

Oxford Biomedica — Burgeoning bioprocessing revenues

Oxford BioMedica — Santen – a global player in ophthalmology

Oxford Biomedica — In a cell and gene therapy sweet spot

Oxford BioMedica — Diversified strategy showing its strength

Oxford BioMedica — Golden age for LentiVector as Axovant signs deal

Oxford BioMedica — Validation achieved, growth expected

Oxford BioMedica — LentiVector platform expanding into haemophilia

Oxford BioMedica — CTL019 approval likely in pALL, ad-com positive

Oxford BioMedica — Lentiviral vector supply for CTL019 driving revenue growth

Oxford BioMedica — CTL019 and product out-licensing to drive 2017

Oxford BioMedica — Update 5 December 2016

Oxford BioMedica — Update 2 December 2016

Oxford BioMedica — Update 24 October 2016

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time